Printer Friendly

Gilead Sciences And World Health Organization Establish New Five-Year Initiative To Prevent Deaths From Visceral Leishmaniasis.

New Delhi, Dec. 13 -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that it will donate 445,000 vials of AmBisome(R) (amphotericin B liposome for injection) over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar.

Visceral leishmaniasis is widespread in South Asia and the Horn of Africa, where it affects hundreds of thousands of people annually. Without treatment, the mortality rate is close to 100 percent. In the Indian subcontinent, where VL is endemic, the WHO Leishmaniasis Expert Committee recommends single-dose AmBisome as the safest, most effective treatment for the disease. AmBisome is approved for the treatment of VL in the United States.

"This commendable donation means that every AmBisome vial will contribute to saving a life," commented Dr. Jorge Alvar, who heads WHO's Leishmaniasis programme in the Department of Control of Neglected Tropical Diseases. "We hope that this commitment by Gilead will encourage other partners to join the fight in overcoming this neglected tropical disease."

"Gilead is proud to expand our long-standing partnership with WHO," said John C. Martin, PhD, Chairman and Chief Executive Officer of Gilead Sciences. "We continually seek to identify new ways to increase access to our anti-infective therapies, and have the highest regard for WHO's efforts to combat VL worldwide. Working in conjunction with health ministries, WHO will now be able to save more lives by expanding patient access to AmBisome."

Gilead has supported WHO's leishmaniasis control program since 1992. Currently Gilead offers AmBisome through the company's access program at no-profit pricing - or pricing that is at or below Gilead's manufacturing cost - in a number of countries hardest hit by VL. If sold at Gilead's no-profit access price, today's donation would cost more than $8 million. The company also donates AmBisome for use in clinical studies aimed at identifying the most effective VL treatment regimens.

These initiatives are part of the Gilead Access Program, which aims to provide wider access to the company's medications to affected populations in the developing world. The Access Program is currently delivering branded or generic versions of Gilead's HIV therapies to 1.8 million patients in developing countries.

For any query with respect to this article or any other content requirement, please contact Editor at htsyndication@hindustantimes.com

Copyright HT Media Ltd.

Provided by Syndigate.info an Albawaba.com company

COPYRIGHT 2011 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:India PRwire
Date:Dec 13, 2011
Words:395
Previous Article:VIP-Verve to redefine every journey you make!
Next Article:Gangavaram responsive to all queries made by Orissa Government.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters